GILD
Price
$113.18
Change
+$0.89 (+0.79%)
Updated
Aug 1 closing price
Capitalization
90.79B
5 days until earnings call
NVS
Price
$115.30
Change
+$1.56 (+1.37%)
Updated
Aug 1 closing price
Capitalization
197.93B
87 days until earnings call
Interact to see
Advertisement

GILD vs NVS

Header iconGILD vs NVS Comparison
Open Charts GILD vs NVSBanner chart's image
Gilead Sciences
Price$113.18
Change+$0.89 (+0.79%)
Volume$5.02M
Capitalization90.79B
Novartis AG
Price$115.30
Change+$1.56 (+1.37%)
Volume$1.93M
Capitalization197.93B
GILD vs NVS Comparison Chart in %
Loading...
GILD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GILD vs. NVS commentary
Aug 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GILD is a StrongBuy and NVS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 02, 2025
Stock price -- (GILD: $112.29 vs. NVS: $113.74)
Brand notoriety: GILD: Notable vs. NVS: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GILD: 107% vs. NVS: 113%
Market capitalization -- GILD: $90.79B vs. NVS: $197.93B
GILD [@Pharmaceuticals: Major] is valued at $90.79B. NVS’s [@Pharmaceuticals: Major] market capitalization is $197.93B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GILD’s FA Score shows that 4 FA rating(s) are green whileNVS’s FA Score has 3 green FA rating(s).

  • GILD’s FA Score: 4 green, 1 red.
  • NVS’s FA Score: 3 green, 2 red.
According to our system of comparison, GILD is a better buy in the long-term than NVS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GILD’s TA Score shows that 4 TA indicator(s) are bullish while NVS’s TA Score has 5 bullish TA indicator(s).

  • GILD’s TA Score: 4 bullish, 3 bearish.
  • NVS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, GILD is a better buy in the short-term than NVS.

Price Growth

GILD (@Pharmaceuticals: Major) experienced а -0.80% price change this week, while NVS (@Pharmaceuticals: Major) price change was -3.17% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.79%. For the same industry, the average monthly price growth was +6.07%, and the average quarterly price growth was +13.61%.

Reported Earning Dates

GILD is expected to report earnings on Oct 23, 2025.

NVS is expected to report earnings on Oct 28, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+0.79% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVS($198B) has a higher market cap than GILD($90.8B). NVS has higher P/E ratio than GILD: NVS (23.38) vs GILD (16.20). GILD YTD gains are higher at: 24.265 vs. NVS (22.753). NVS has higher annual earnings (EBITDA): 18.3B vs. GILD (10.5B). NVS has more cash in the bank: 14B vs. GILD (7.26B). GILD has less debt than NVS: GILD (25B) vs NVS (26.3B). NVS has higher revenues than GILD: NVS (46.7B) vs GILD (27.1B).
GILDNVSGILD / NVS
Capitalization90.8B198B46%
EBITDA10.5B18.3B57%
Gain YTD24.26522.753107%
P/E Ratio16.2023.3869%
Revenue27.1B46.7B58%
Total Cash7.26B14B52%
Total Debt25B26.3B95%
FUNDAMENTALS RATINGS
GILD vs NVS: Fundamental Ratings
GILD
NVS
OUTLOOK RATING
1..100
1458
VALUATION
overvalued / fair valued / undervalued
1..100
21
Undervalued
16
Undervalued
PROFIT vs RISK RATING
1..100
1620
SMR RATING
1..100
2929
PRICE GROWTH RATING
1..100
1853
P/E GROWTH RATING
1..100
10082
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVS's Valuation (16) in the Pharmaceuticals Major industry is in the same range as GILD (21) in the Biotechnology industry. This means that NVS’s stock grew similarly to GILD’s over the last 12 months.

GILD's Profit vs Risk Rating (16) in the Biotechnology industry is in the same range as NVS (20) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to NVS’s over the last 12 months.

GILD's SMR Rating (29) in the Biotechnology industry is in the same range as NVS (29) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to NVS’s over the last 12 months.

GILD's Price Growth Rating (18) in the Biotechnology industry is somewhat better than the same rating for NVS (53) in the Pharmaceuticals Major industry. This means that GILD’s stock grew somewhat faster than NVS’s over the last 12 months.

NVS's P/E Growth Rating (82) in the Pharmaceuticals Major industry is in the same range as GILD (100) in the Biotechnology industry. This means that NVS’s stock grew similarly to GILD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GILDNVS
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
36%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
45%
Bullish Trend 2 days ago
43%
Momentum
ODDS (%)
Bullish Trend 2 days ago
58%
Bearish Trend 2 days ago
40%
MACD
ODDS (%)
Bullish Trend 2 days ago
65%
Bearish Trend 2 days ago
47%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
47%
Bearish Trend 2 days ago
43%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
61%
Bearish Trend 2 days ago
40%
Advances
ODDS (%)
Bullish Trend 3 days ago
58%
Bullish Trend 10 days ago
50%
Declines
ODDS (%)
Bearish Trend 15 days ago
50%
Bearish Trend 15 days ago
44%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
57%
Bullish Trend 2 days ago
49%
Aroon
ODDS (%)
Bullish Trend 2 days ago
58%
Bullish Trend 2 days ago
42%
View a ticker or compare two or three
Interact to see
Advertisement
GILD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ILOW40.760.16
+0.39%
AB Active ETFs Inc.
FHYS23.150.01
+0.06%
Federated Hermes Short Duration HY ETF
BBCA80.00-0.45
-0.56%
JPMorgan BetaBuilders Canada ETF
BAUG46.70-0.45
-0.95%
Innovator U.S. Equity Buffer ETF Aug
QQH68.04-1.95
-2.79%
HCM Defender 100 Index ETF

GILD and

Correlation & Price change

A.I.dvisor indicates that over the last year, GILD has been loosely correlated with BMY. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if GILD jumps, then BMY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GILD
1D Price
Change %
GILD100%
+0.79%
BMY - GILD
47%
Loosely correlated
+2.12%
GSK - GILD
44%
Loosely correlated
+1.10%
SNY - GILD
43%
Loosely correlated
+2.43%
PFE - GILD
43%
Loosely correlated
+0.86%
NVS - GILD
42%
Loosely correlated
+1.37%
More

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
+1.37%
GSK - NVS
66%
Closely correlated
+1.10%
AZN - NVS
60%
Loosely correlated
+1.18%
PFE - NVS
56%
Loosely correlated
+0.86%
JNJ - NVS
54%
Loosely correlated
+1.57%
SNY - NVS
49%
Loosely correlated
+2.43%
More